See more : One World Universe Inc. (OWUV) Income Statement Analysis – Financial Results
Complete financial analysis of Vincerx Pharma, Inc. (VINC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vincerx Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Leo Holdings Corp. II Redeemabl (LHC-WT) Income Statement Analysis – Financial Results
- Kanto Denka Kogyo Co., Ltd. (4047.T) Income Statement Analysis – Financial Results
- SSC Security Services Corp. (SECUF) Income Statement Analysis – Financial Results
- De Nora India Limited (DENORA.BO) Income Statement Analysis – Financial Results
- SG Micro Corp (300661.SZ) Income Statement Analysis – Financial Results
Vincerx Pharma, Inc. (VINC)
About Vincerx Pharma, Inc.
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 915.00K | 939.00K | 340.00K | 173.00K | 173.00K |
| Gross Profit | -915.00K | -939.00K | -340.00K | -173.00K | -173.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 28.97M | 52.15M | 40.08M | 7.12M | 0.00 |
| General & Administrative | 13.64M | 18.95M | 22.58M | 3.60M | 54.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 44.95K |
| SG&A | 13.64M | 18.95M | 22.58M | 3.60M | 45.00K |
| Other Expenses | 0.00 | 1.24M | -8.00K | -8.00K | 0.00 |
| Operating Expenses | 42.61M | 71.11M | 62.66M | 10.71M | 45.00K |
| Cost & Expenses | 42.61M | 71.11M | 62.66M | 10.71M | 45.00K |
| Interest Income | 1.25M | 664.00K | 0.00 | 54.27K | 54.27K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 8.00K | 0.00 |
| Depreciation & Amortization | 52.00K | 939.00K | 340.00K | 5.71M | 54.00K |
| EBITDA | -42.61M | -68.67M | -62.66M | -10.71M | 9.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -42.61M | -73.57M | -62.66M | -10.71M | -45.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.45M | 8.21M | 23.35M | -5.91M | 0.00 |
| Income Before Tax | -40.16M | -65.37M | -39.31M | -10.72M | -45.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -8.21M | -23.70M | 8.00K | -54.00 |
| Net Income | -40.16M | -57.16M | -15.61M | -10.73M | -45.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.89 | -2.72 | -0.91 | -0.77 | -0.01 |
| EPS Diluted | -1.89 | -2.72 | -0.91 | -0.77 | -0.01 |
| Weighted Avg Shares Out | 21.30M | 21.03M | 17.18M | 13.98M | 5.20M |
| Weighted Avg Shares Out (Dil) | 21.30M | 21.03M | 17.18M | 13.98M | 5.20M |
Why Is Vincerx Pharma (VINC) Stock Down 64% Today?
Vincerx Pharma (NASDAQ: VINC ) stock is falling hard on Tuesday after releasing preliminary data from a Phase 1 clinical trial. Vincerx Pharma's cancer treatments did so potential in preliminary study results.
Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024
VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors
Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
VIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a virtual investor event on April 8 at 2:00 PM PT
Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
Management to host virtual investor event on April 8 to highlight preliminary Phase 1 Data for VIP236, our first-in-class small molecule-drug conjugate (SMDC) Management to host virtual investor event on April 8 to highlight preliminary Phase 1 Data for VIP236,...
Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma
Investigators from the National Institutes of Health (NIH) report 2 partial responses (PR) in 3 peripheral T-cell lymphoma (PTCL) patients and 1 PR in 2 double-hit diffuse large b-cell lymphoma (DH-DLBCL) patients in ongoing dose-escalation trial of enitociclib in combination...
Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023
Poster on VIP943, a novel CD123-targeted antibody-drug conjugate (ADC) from our VersAptx™ platform, showcases selectivity, activity, and safety of VIP943
Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Phase 1 dose escalation for VIP943 - first antibody-drug conjugate (ADC) from VersAptx™, versatile and adaptable, next-generation bioconjugation platform - moves quickly into 2 nd cohort
Vincerx Pharma To Present Three Posters at ASH 2023 in December
VIP943 poster supports selectivity and safety of lead CD123 ADC, VIP943, currently in Phase 1 VIP924 poster shows this novel CXCR5-ADC compares favorably with other ADCs in clinical development Enitociclib poster expands potential clinical indications PALO ALTO, Calif., Nov. 02,...
Vincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023
PALO ALTO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that Vincerx's CEO Ahmed Hamdy, M.D. and the...
Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943
Phase 1 trial enrolling patients with relapsed/refractory AML, MDS and B-cell ALL Phase 1 trial enrolling patients with relapsed/refractory AML, MDS and B-cell ALL
Source: https://incomestatements.info
Category: Stock Reports